Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19

Molecular Partners AG (NASDAQ:MOLN) and its partner Novartis AG (NYSE:NVS), have requested FDA Emergency Use Authorization (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19.

  • This submission is based on the totality of the data from clinical and preclinical studies, including the results of the Phase 2 portion of the EMPATHY study, which enrolled 407 symptomatic COVID-19 patients.
  • Related: Novartis To In-License COVID-19 Treatment From Molecular Partners, After Encouraging Mid-Stage Data.
  • Ensovibep is a DARPin therapeutic candidate designed specifically to inhibit target cell entry of SARS-CoV-2, the virus that causes COVID-19. 
  • DARPin's (Designed Ankyrin Repeat Proteins) are mono or multi-specific protein-based therapies designed to engage their targets for various effects specifically. E
  • Price Action: MOLN shares traded 0.27% higher at $26.19, NVS shares are up 0.72% at $87.83 during the premarket session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.